Laura E. Egolf

Laura E. Egolf

Auto-generated profile, based on publicly available information

Laura E. Egolf

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Rockville, MD 20850-9772

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cell Reports
Verified
Journal Article
Open access
JRJo Lynne Rokita
Jo Lynne Rokita
KRKomal Rathi
Komal Rathi
MCMaria F. Cardenas
Maria F. Cardenas
KUKristen A. Upton
Kristen A. Upton
JJJoy Jayaseelan
Joy Jayaseelan
JMJohn M. Maris
John M. Maris
Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)-many of which are refractory to current standard-of-care treatments-from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer.

27 March 2018 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
LRLaura E. Ritenour
Laura E. Ritenour
MRMichael P. Randall
Michael P. Randall
KBKristopher R. Bosse
Kristopher R. Bosse
SDSharon J. Diskin
Sharon J. Diskin

1 September 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LELaura E. Egolf
Laura E. Egolf
ZVZalman Vaksman
Zalman Vaksman
GLGonzalo Lopez
Gonzalo Lopez
JRJo Lynne Rokita
Jo Lynne Rokita
AMApexa Modi
Apexa Modi
SDSharon J. Diskin
Sharon J. Diskin

25 September 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
MRMaryam Rafati
Maryam Rafati
LGLillian M Guenther
Lillian M Guenther
LELaura E Egolf
Laura E Egolf
MGMatthew Gianferante
Matthew Gianferante
JKJung Kim
Jung Kim
LMLisa Mirabello
Lisa Mirabello
Osteosarcoma, the most common childhood bone tumor, can occur in rare cancer predisposition syndromes; however, most are sporadic with no known predisposing factors. We investigated the frequency of SMARCAL1 putative pathogenic variants in our large ongoing study of 2119 osteosarcoma patients, their relation to patient characteristics, and the population prevalence. Our analysis uncovered a higher frequency of SMARCAL1 pathogenic variants across 3 osteosarcoma patient sets (1.8%, n = 2119) than in 2625 comparably sequenced cancer-free individuals (0.3%; P < .001). Patients with SMARCAL1 pathogenic variants had statistically significantly improved overall survival compared with patients without these variants (hazard ratio [HR] = 0.36, 95% confidence interval [CI] = 0.14 to 0.96; P = .034). In the UK Biobank (469 557 exomes), there was a 33-fold increased risk of osteosarcoma in individuals with SMARCAL1 pathogenic variants. These results identify SMARCAL1 as a new osteosarcoma predisposition gene and thus warrant follow-up to identify the mechanisms by which SMARCAL1 contributes to the etiology of osteosarcoma.

16 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJoshua A. Shapiro
Joshua A. Shapiro
KGKrutika S. Gaonkar
Krutika S. Gaonkar
CSCandace L. Savonen
Candace L. Savonen
SSStephanie Spielman
Stephanie Spielman
CBChante J. Bethell
Chante J. Bethell
PCPacific Pediatric Neuro-Oncology Consortium
Pacific Pediatric Neuro-Oncology Consortium
Summary: Pediatric brain and spinal cancer are the leading disease-related cause of death in children, thus we urgently need curative therapeutic strategies for these tumors. To accelerate such discoveries, the Children’s Brain Tumor Network and Pacific Pediatric Neuro-Oncology Consortium created a systematic process for tumor biobanking, model generation, and sequencing with immediate access to harmonized data. We leverage these data to create OpenPBTA, an open collaborative project which establishes over 40 scalable analysis modules to genomically characterize 1,074 pediatric brain tumors. Transcriptomic classification reveals that TP53 loss is a significant marker for poor overall survival in ependymomas and H3 K28-altered diffuse midline gliomas and further identifies universal TP53 dysregulation in mismatch repair-deficient hypermutant high-grade gliomas. OpenPBTA is a foundational analysis platform actively being applied to other pediatric cancers and inform molecular tumor board decision-making, making it an invaluable resource to the pediatric oncology community. In Brief: The OpenPBTA is a global, collaborative open-science initiative which brought together researchers and clinicians to genomically characterize 1,074 pediatric brain tumors and 22 patient-derived cell lines. Shapiro, et. al create over 40 open-source, scalable modules to perform cancer genomics analyses and provide a richly-annotated somatic dataset across 58 brain tumor histologies. The OpenPBTA framework can be used as a model for large-scale data integration to inform basic research, therapeutic target identification, and clinical translation. Highlights: OpenPBTA collaborative analyses establish resource for 1,074 pediatric brain tumors NGS-based WHO-aligned integrated diagnoses generated for 641 of 1,074 tumors RNA-Seq analysis infers medulloblastoma subtypes, TP53 status, and telomerase activity OpenPBTA will accelerate therapeutic translation of genomic insights